This article was originally published in The Gray Sheet
Prudential Health Plans joins a growing list of third party payers that are reimbursing for the ThinPrep Pap Test for cervical cancer screening, the company told investors at a June 9 Piper Jaffray conference in Minneapolis. The test, which sells at a list price of $475 for 40 tests, has been accepted for reimbursement by independent Blue Cross and Blue Shield health plans in New York (Empire), North Carolina, Maryland, Montana, and West Virginia (Mountain State) and by Oxford Health Plans. Pennsylvania-based Highmark Blue Cross and Blue Shield rejected a reimbursement request by Cytyc earlier this year citing a lack of evidence to demonstrate cost effectiveness of the device ("The Gray Sheet" Feb. 16, p. 9). Cytyc is considering seeking labeling to allow for screening for common sexually transmitted diseases
You may also be interested in...
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.